FDA Approves Frontline Obinutuzumab for Follicular Lymphoma

November 16, 2017 – The FDA has approved obinutuzumab in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma, according to Genentech, the manufacturer of the therapy. The approval which is for patients with stage II bulky, III or IV disease, is based on data from the phase III GALLIUM study, in which combining obinutuzumab with chemotherapy in the first-line setting reduced … (leggi tutto)